Figure 3. Overall Survival (Panel A) and Time to the Progression of Disease (Panel B) among Patients with Gliomas Treated with Carmustine, According to the Methylation Status of the MGMT Promoter.

Both overall survival and the time to the progression of disease were significantly greater in the group of patients with methylation of the MGMT promoter than in the group without methylation. The association was independent of the type of tumor, the patient's age, and the Karnofsky score for performance status.

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.